NZ609324A - Biomarker for alzheimer’s disease or mild cognitive impairment - Google Patents

Biomarker for alzheimer’s disease or mild cognitive impairment

Info

Publication number
NZ609324A
NZ609324A NZ609324A NZ60932411A NZ609324A NZ 609324 A NZ609324 A NZ 609324A NZ 609324 A NZ609324 A NZ 609324A NZ 60932411 A NZ60932411 A NZ 60932411A NZ 609324 A NZ609324 A NZ 609324A
Authority
NZ
New Zealand
Prior art keywords
candidate
level
administered
blood
human animal
Prior art date
Application number
NZ609324A
Other languages
English (en)
Inventor
Yoshiaki Sato
Ken Aoshima
Francois Bernier
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NZ609324A publication Critical patent/NZ609324A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/20Oxygen containing
    • Y10T436/203332Hydroxyl containing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ609324A 2010-10-20 2011-06-23 Biomarker for alzheimer’s disease or mild cognitive impairment NZ609324A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010235203 2010-10-20
US201061424885P 2010-12-20 2010-12-20
JP2010282938 2010-12-20
PCT/JP2011/064487 WO2012053255A1 (ja) 2010-10-20 2011-06-23 アルツハイマー病又は軽度認知症のバイオマーカー

Publications (1)

Publication Number Publication Date
NZ609324A true NZ609324A (en) 2014-09-26

Family

ID=45974981

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ609324A NZ609324A (en) 2010-10-20 2011-06-23 Biomarker for alzheimer’s disease or mild cognitive impairment

Country Status (10)

Country Link
US (1) US9581604B2 (https=)
EP (1) EP2631646B1 (https=)
JP (1) JP5695075B2 (https=)
AU (1) AU2011319319B2 (https=)
BR (1) BR112013009592A2 (https=)
CA (1) CA2814385C (https=)
IN (1) IN2013CN02996A (https=)
NZ (1) NZ609324A (https=)
RU (1) RU2563987C2 (https=)
WO (1) WO2012053255A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212084D0 (en) * 2012-07-06 2012-08-22 Randox Lab Ltd Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment
EP3267200A4 (en) * 2015-03-06 2018-08-22 Niigata University Biomarker of dementia with lewy bodies
ES2657414T3 (es) * 2015-11-20 2018-03-05 Geroa Diagnostics, S.L Uso de la lactoferrina en el diagnóstico o el pronóstico de la enfermedad de Alzheimer
CN114410774A (zh) * 2022-02-17 2022-04-29 杭州怡健医疗科技有限公司 一种应用于阿尔茨海默氏症的患病风险评估方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088811A2 (en) * 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
JPWO2007097461A1 (ja) * 2006-02-27 2009-07-16 国立大学法人 熊本大学 C型肝炎治療用抗体
US7645748B2 (en) * 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
RU2356058C2 (ru) * 2006-11-27 2009-05-20 Александр Васильевич Мальцев Способ диагностики амилоидоза при болезни альцгеймера и комплект средств для его осуществления

Also Published As

Publication number Publication date
CA2814385C (en) 2017-10-24
WO2012053255A1 (ja) 2012-04-26
AU2011319319A1 (en) 2013-05-02
EP2631646B1 (en) 2016-10-19
US20130266589A1 (en) 2013-10-10
BR112013009592A2 (pt) 2016-07-12
US9581604B2 (en) 2017-02-28
JP5695075B2 (ja) 2015-04-01
RU2013122853A (ru) 2014-11-27
CA2814385A1 (en) 2012-04-26
EP2631646A1 (en) 2013-08-28
IN2013CN02996A (https=) 2015-08-14
EP2631646A4 (en) 2014-05-07
AU2011319319B2 (en) 2015-07-30
RU2563987C2 (ru) 2015-09-27
JPWO2012053255A1 (ja) 2014-02-24

Similar Documents

Publication Publication Date Title
Zhang et al. Roles of microRNA-34a targeting SIRT1 in mesenchymal stem cells
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
WO2014036495A3 (en) Diagnostic assays and kits for detection of folate receptor 1
WO2011133668A3 (en) Methods and compositions for the treatment of cancer
WO2010091049A3 (en) Diagnosis and treatment of cancer
EA201400491A1 (ru) Сопровождающая диагностика для терапии с антигиалуроновым агентом и способы ее применения
WO2014179765A3 (en) Novel human mirnas for use in diagnosis, prognosis and therapy of human conditions and diseases
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
BR112015022934A2 (pt) esteroides neuroativos, composições, e uso do mesmo
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
CA2863393A1 (en) A multi-biomarker-based outcome risk stratification model for pediatric septic shock
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
AR080361A1 (es) Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk)
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
BR112013023970A2 (pt) composição farmacêutica, dispositivo, inibidor de hdac, kit, método de pré-tratamento de um ser humano que sofre de câncer e método de avaliação do efeito de uma substância sobre a sensibilidade a chop de linhagens celulares
WO2015034886A3 (en) Wellness panel for companion animals
BR112012026224A2 (pt) métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
NZ609324A (en) Biomarker for alzheimer’s disease or mild cognitive impairment
WO2016126844A8 (en) Novel methods for early identification of bone healing ability in injured patients
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2022001087A (es) Ergotioneina, s-metil-ergotioneina, y usos de las mismas.
WO2008089135A3 (en) Identification of biomarkers predictive of dasatinib effects in cancer cells

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUN 2016 BY DENNEMEYER + CO

Effective date: 20150522

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUN 2017 BY DENNEMEYER + CO

Effective date: 20160520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUN 2018 BY DENNEMEYER + CO.

Effective date: 20170520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUN 2019 BY DENNEMEYER + CO

Effective date: 20180526

LAPS Patent lapsed